(Press-News.org) WASHINGTON (March 29, 2014) — Transcatheter aortic valve replacement with a self-expanding valve prosthesis for the first time has demonstrated significantly lower death rates at one year compared with conventional surgical valve replacement in high-risk patients with severe aortic stenosis, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.
Worldwide, an estimated 300,000 people have severe aortic stenosis – a faulty valve in the main artery carrying blood out of the heart – and roughly a third of them are deemed unable to withstand the standard treatment of open-heart surgery to replace the valve. But if the condition is left untreated, risk of death is 25 percent the first year after symptoms appear and rises to 50 percent the second year. Replacement valves delivered by a catheter, usually through the groin or chest, have been developed as a less invasive alternative to open-heart surgery.
The CoreValve U.S. Pivotal High Risk Trial enrolled patients with an assessed increased risk of death from aortic valve surgery. Of 795 patients randomly assigned to valve replacement by catheter or surgery, 747 patients underwent one of the procedures: 390 in the transcatheter aortic valve replacement (TAVR) arm and 357 in the surgical aortic valve replacement arm. The average age was about 83 years in both groups. The results exceeded the initial non-inferiority goal and, by pre-design, then moved on to a superiority analysis. Death rates at 30 days were not significantly different, with a 3.3 percent death rate for TAVR and 4.5 percent for surgery. A significant difference emerged at the one-year primary endpoint of all-cause mortality: 14.2 percent for TAVR with CoreValve compared with 19.1 percent for surgical replacement.
"This is the first prospective study of any device that suggests TAVR is superior to [surgery] in a predefined population of patients, and that's a provocative finding," said David H. Adams, M.D., professor and chairman of the Department of Cardiothoracic Surgery at Mount Sinai Medical Center and co-principal investigator of the study. He emphasized the "outstanding outcomes" in the surgical arm: "The low mortality rates with conventional surgery far exceeded the predicted mortality according to the Society of Thoracic Surgeons predictive model. In order to pass a superiority threshold, transcatheter treatment with the CoreValve device had to exceed excellent surgical outcomes."
Exploratory analyses also showed the one-year rate for heart attack, stroke or related death was significantly lower for TAVR at 20.4 percent compared with 27.3 percent for surgical replacement.
"We also performed multiple different subgroup analyses for one-year death rates and found the survival benefit of TAVR with CoreValve was consistent across all clinical subgroups we examined, regardless of thresholds," Adams said.
The 30-day observed death rates for TAVR and surgical valve replacement were much lower than the anticipated rate of 15 percent, Adams said, suggesting that the patient population may have had lower risks than intended. In addition to the STS score, frailty and other disabilities were considered in the evaluation of risk. Randomization ensured a robust trial nonetheless, he said, adding that this study confirmed that current risk assessment models, including expert physician reviews, overestimate contemporary surgical risks.
A potential limitation of the study is the higher dropout rate for patients randomly assigned to surgery, as reported with previous TAVR trials. Forty patients assigned to surgery dropped out of the study before treatment, while only four assigned to the TAVR arm dropped out. The trial was designed with this anticipated attrition rate, and a sensitivity analysis confirmed that there were no significant differences in the risk profiles between patients who underwent the assigned surgical treatment and those who withdrew, Adams said.
"We are confident that the higher withdrawal rate in the surgical arm did not affect our findings," he said.
Strong results from the other arm of CoreValve's U.S. Pivotal Trial with patients at extreme risk for standard aortic valve-replacement surgery were reported in October and led to Food and Drug Administration approval for the device in this population.
INFORMATION:
The study was funded by Medtronic, Inc. The Icahn School of Medicine at Mount Sinai receives royalties for intellectual property developed by Adams for mitral and tricuspid repair products now owned by Edwards Lifesciences and Medtronic.
This study will be simultaneously published online in the New England Journal of Medicine at the time of presentation.
The ACC's Annual Scientific Session brings together cardiologists and cardiovascular specialists from around the world each year to share the newest discoveries in treatment and prevention. Follow @ACCMediaCenter and #ACC14 for the latest news from the meeting.
The American College of Cardiology is a nonprofit medical society comprised of 47,000 physicians, surgeons, nurses, physician assistants, pharmacists and practice managers. The College is dedicated to transforming cardiovascular care, improving heart health and advancing quality improvement, patient-centered care, payment innovation and professionalism. The ACC also leads the formulation of important cardiovascular health policy, standards and guidelines. It bestows credentials upon cardiovascular specialists, provides professional education, supports and disseminates cardiovascular research, and operates national registries to measure and promote quality care. For more information, visit CardioSource.org.
Fewer deaths with self-expanding TAVR versus surgery at 1 year
Transcatheter aortic valve replacement treats severe aortic stenosis
2014-03-31
ELSE PRESS RELEASES FROM THIS DATE:
Renal denervation shows no benefit in resistant hypertension
2014-03-31
WASHINGTON (March 29, 2014) — Renal denervation fell short of primary and secondary efficacy goals in patients with severe resistant hypertension but did meet the primary safety endpoints, according to keenly awaited data from SYMPLICITY HTN-3 presented at the American College of Cardiology's 63rd Annual Scientific Session. This pivotal trial is the largest study conducted of renal artery denervation as a treatment for resistant hypertension and the most rigorously designed, including blinding and a sham treatment in the control arm.
Hypertension increases risks for heart ...
Efforts to curb hospital readmissions take center stage
2014-03-31
WASHINGTON (March 29, 2014) — Strategies aimed at reducing the number of patients with heart failure and other cardiovascular conditions who find themselves back in the hospital after discharge were identified in six new studies presented at the American College of Cardiology's 63rd Annual Scientific Session.
One out of five Medicare patients with heart failure is readmitted to the hospital within just one month of discharge, a fact that is not only bad news for patients who would most likely prefer to avoid another hospital stay, but it also places intense economic pressures ...
Primary cardiovascular disease prevention is leaving the office
2014-03-31
MINNEAPOLIS, MN – March 30, 2014 – Early results from HeartBeat Connections, a telemedicine program supported by the Minneapolis Heart Institute Foundation (MHIF), suggest effective primary prevention for cardiovascular disease (CVD) may be achieved with a team-based approach that integrates office visits with supplemental phone coaching. HeartBeat Connections provides dietitian- and nurse-led coaching over the phone to adults at high risk for CVD, with the goal of helping to improve and control key CVD risk factors. Gretchen Benson, RD, CDE, Healthcare Systems Integration ...
Adults with inherited high cholesterol are underdiagnosed and undertreated
2014-03-31
MINNEAPOLIS, MN – March 30, 2014 – An estimated 1 in 500 people worldwide suffer from familial hypercholesterolaemia (FH), an inherited condition of extremely high cholesterol that is associated with premature heart disease and death. Despite this high prevalence, recent research funded by the Minneapolis Heart Institute Foundation (MHIF) confirms FH is underdiagnosed and undertreated. Thomas Knickelbine, MD, Preventive Cardiology Director at the Minneapolis Heart Institute at Abbott Northwestern Hospital, will present the results of research aimed at identifying just ...
Evolocumab superior to ezetimibe in lowering LDL cholesterol
2014-03-31
WASHINGTON (March 30, 2014) — Evolocumab, an injected form of a class of drugs called PCSK9 inhibitors that lower low-density lipoprotein cholesterol, also known as LDL-C or "bad cholesterol," outperformed ezetimibe with few side effects in patients unable to take statins, according to research from GAUSS-2 presented at the American College of Cardiology's 63rd Annual Scientific Session.
High LDL cholesterol is considered a major risk factor for cardiovascular disease. Statins are commonly prescribed to reduce that risk. Currently ezetimibe is one of the few options ...
Head-to-head study favors balloon-expandable transcatheter heart valves
2014-03-31
WASHINGTON (March 30, 2014) — A first-ever randomized head-to-head comparison of two devices commonly used to treat the age-related disease aortic stenosis finds balloon-expandable transcatheter valves result in more successful procedures and relieve symptoms more frequently than self-expanding valves, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.
Aortic stenosis is a condition in which a crucial valve in the heart ceases to function properly. The only cure is to replace the valve, either through open heart surgery ...
Higher risks without cardio benefits halt study of aleglitazar
2014-03-31
WASHINGTON (March 30, 2014) — The phase III AleCardio trial was ended early when patients with type 2 diabetes and recent acute coronary syndrome who were treated with aleglitazar showed higher rates of heart failure, kidney events and gastrointestinal bleeding with no offsetting cardiovascular benefits, according to data presented at the American College of Cardiology's 63rd Annual Scientific Session. All other studies with the drug have been stopped as well.
Aleglitazar sparked interest for this patient population because of its dual action on two subtypes of the PPAR ...
Darapladib falls short in chronic coronary heart disease
2014-03-31
WASHINGTON (March 30, 2014) — The novel inflammation inhibitor darapladib showed no primary-endpoint advantage over placebo in patients with chronic coronary heart disease treated with a high level of background care, although it did suggest possible benefits for more specific coronary artery-related endpoints, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session. STABILITY is the first study to test this inflammation-prevention mechanism for reducing the likelihood that plaque will become an artery-blocking clot.
Darapladib ...
Evolocumab safely drops LDL cholesterol well below statin-only baseline
2014-03-31
WASHINGTON (March 30, 2014) — The monoclonal antibody evolocumab produced highly significant reductions in low-density lipoprotein (LDL) cholesterol, the "bad cholesterol," as an add-on to statins in all treatment groups, according to data from the LAPLACE-2 study presented at the American College of Cardiology's 63rd Annual Scientific Session.
LDL cholesterol is considered a major risk factor for cardiovascular disease. "High-risk patients – such as those with clinical cardiovascular disease, high LDL cholesterol levels or diabetes – are ideally treated with high-intensity ...
Anti-gout medication colchicine helps patients with recurrent pericarditis
2014-03-31
WASHINGTON (March 30, 2014) — A medication traditionally used to treat gout is also effective at treating recurrent pericarditis, an inflammation of the sac-like covering around the heart, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.
In the first multicenter, double-blind trial to look at the use of colchicine for multiple recurrences of pericarditis, 240 patients were randomly assigned to either the study drug or placebo to examine the primary endpoint of recurrent pericarditis. The rate of disease recurrence ...
LAST 30 PRESS RELEASES:
South Korea completes delivery of ITER vacuum vessel sectors
Global research team develops advanced H5N1 detection kit to tackle avian flu
From food crops to cancer clinics: Lessons in extermination resistance
Scientists develop novel high-fidelity quantum computing gate
Novel detection technology alerts health risks from TNT metabolites
New XR simulator improves pediatric nursing education
New copper metal-organic framework nanozymes enable intelligent food detection
The Lancet: Deeply entrenched racial and geographic health disparities in the USA have increased over the last two decades—as life expectancy gap widens to 20 years
2 MILLION mph galaxy smash-up seen in unprecedented detail
Scientists find a region of the mouse gut tightly regulated by the immune system
How school eligibility influences the spread of infectious diseases: Insights for future outbreaks
UM School of Medicine researchers link snoring to behavioral problems in adolescents without declines in cognition
The Parasaurolophus’ pipes: Modeling the dinosaur’s crest to study its sound #ASA187
St. Jude appoints leading scientist to create groundbreaking Center of Excellence for Structural Cell Biology
Hear this! Transforming health care with speech-to-text technology #ASA187
Exploring the impact of offshore wind on whale deaths #ASA187
Mass General Brigham and BIDMC researchers unveil an AI protein engineer capable of making proteins ‘better, faster, stronger’
Metabolic and bariatric surgery safe and effective for patients with severe obesity
Smarter city planning: MSU researchers use brain activity to predict visits to urban areas
Using the world’s fastest exascale computer, ACM Gordon Bell Prize-winning team presents record-breaking algorithm to advance understanding of chemistry and biology
Jeffrey Hubbell joins NYU Tandon to lead new university-wide health engineering initiative & expand the school’s bioengineering focus
Fewer than 7% of global hotspots for whale-ship collisions have protection measures in place
Oldies but goodies: Study shows why elderly animals offer crucial scientific insights
Math-selective US universities reduce gender gap in STEM fields
Researchers identify previously unknown compound in drinking water
Chloronitramide anion – a newly characterized contaminant prevalent in chloramine treated tap water
Population connectivity shapes cultural complexity in chimpanzees
Direct hearing tests show that minke whales can hear high-frequency sounds
Whale-ship collision risk mapped across Earth’s oceans
Bye-bye microplastics: new plastic is recyclable and fully ocean-degradable
[Press-News.org] Fewer deaths with self-expanding TAVR versus surgery at 1 yearTranscatheter aortic valve replacement treats severe aortic stenosis